Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.

Duek A, Lundberg P, Shimizu T, Grisouard J, Karow A, Kubovcakova L, Hao-Shen H, Dirnhofer S, Skoda RC.

Blood. 2014 Jun 19;123(25):3943-50. doi: 10.1182/blood-2013-07-514208. Epub 2014 May 12.

3.

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA.

PLoS One. 2006 Dec 20;1:e18.

4.

Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN.

Grisouard J, Shimizu T, Duek A, Kubovcakova L, Hao-Shen H, Dirnhofer S, Skoda RC.

Blood. 2015 Mar 26;125(13):2131-40. doi: 10.1182/blood-2014-08-594572. Epub 2015 Jan 16.

PMID:
25595737
5.

Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.

Hattori N, Fukuchi K, Nakashima H, Maeda T, Adachi D, Saito B, Yanagisawa K, Matsuda I, Nakamaki T, Gomi K, Tomoyasu S.

Int J Hematol. 2008 Sep;88(2):181-8. doi: 10.1007/s12185-008-0129-9. Epub 2008 Jul 10.

PMID:
18612778
6.

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.

Li J, Spensberger D, Ahn JS, Anand S, Beer PA, Ghevaert C, Chen E, Forrai A, Scott LM, Ferreira R, Campbell PJ, Watson SP, Liu P, Erber WN, Huntly BJ, Ottersbach K, Green AR.

Blood. 2010 Sep 2;116(9):1528-38. doi: 10.1182/blood-2009-12-259747. Epub 2010 May 20.

7.

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.

Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K, Oku S, Abe H, Katayose KS, Kubuki Y, Kusumoto K, Hasuike S, Tahara Y, Nagata K, Matsuda T, Ohshima K, Harada M, Shimoda K.

Leukemia. 2008 Jan;22(1):87-95. Epub 2007 Nov 22.

PMID:
18033315
8.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
9.

Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model.

Kubovcakova L, Lundberg P, Grisouard J, Hao-Shen H, Romanet V, Andraos R, Murakami M, Dirnhofer S, Wagner KU, Radimerski T, Skoda RC.

Blood. 2013 Feb 14;121(7):1188-99. doi: 10.1182/blood-2012-03-415646. Epub 2012 Dec 20.

10.

JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies.

Kreft A, Kindler T, Springer E, Kirkpatrick CJ.

Virchows Arch. 2011 Nov;459(5):521-7. doi: 10.1007/s00428-011-1154-2. Epub 2011 Oct 18.

PMID:
22006129
11.

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.

Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, Skoda RC.

Blood. 2008 Apr 15;111(8):3931-40. Epub 2007 Dec 26.

12.

JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.

Hasan S, Lacout C, Marty C, Cuingnet M, Solary E, Vainchenker W, Villeval JL.

Blood. 2013 Aug 22;122(8):1464-77. doi: 10.1182/blood-2013-04-498956. Epub 2013 Jul 17.

13.

A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.

Marty C, Lacout C, Droin N, Le Couédic JP, Ribrag V, Solary E, Vainchenker W, Villeval JL, Plo I.

Leukemia. 2013 Nov;27(11):2187-95. doi: 10.1038/leu.2013.102. Epub 2013 Apr 5.

PMID:
23558526
14.

JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.

Duletić AN, Dekanić A, Hadzisejdić I, Kusen I, Matusan-Ilijas K, Grohovac D, Grahovac B, Jonjić N.

Coll Antropol. 2012 Sep;36(3):859-65.

PMID:
23213945
15.

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR.

N Engl J Med. 2007 Feb 1;356(5):459-68.

16.

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.

Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.

Semin Thromb Hemost. 2006 Apr;32(3):174-207. Review.

PMID:
16673274
17.

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.

Eur J Haematol. 2007 Dec;79(6):508-15. Epub 2007 Oct 23.

PMID:
17961178
18.

Characterization of murine JAK2V617F-positive myeloproliferative disease.

Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW.

Cancer Res. 2006 Dec 1;66(23):11156-65.

19.

Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of essential thrombocythemia.

Mossuz P, Arlotto M, Hermouet S, Bouamrani A, Lippert E, Girodon F, Dobo I, Vincent P, Cahn JY, Berger F.

Exp Hematol. 2008 Dec;36(12):1642-7. doi: 10.1016/j.exphem.2008.07.013. Epub 2008 Oct 5.

PMID:
18838204
20.

Polycythemia vera: scientific advances and current practice.

Tefferi A, Spivak JL.

Semin Hematol. 2005 Oct;42(4):206-20. Review.

PMID:
16210034
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk